EP0972047A2 - Proteines a capside principale de papillomavirus et leur utilisation a des fins de diagnostic, de therapie et de vaccination - Google Patents

Proteines a capside principale de papillomavirus et leur utilisation a des fins de diagnostic, de therapie et de vaccination

Info

Publication number
EP0972047A2
EP0972047A2 EP98928070A EP98928070A EP0972047A2 EP 0972047 A2 EP0972047 A2 EP 0972047A2 EP 98928070 A EP98928070 A EP 98928070A EP 98928070 A EP98928070 A EP 98928070A EP 0972047 A2 EP0972047 A2 EP 0972047A2
Authority
EP
European Patent Office
Prior art keywords
dna
papilloma virus
protein
papillomavirus
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98928070A
Other languages
German (de)
English (en)
Inventor
Ethel-Michele De Villiers-Zur Hausen
Harald Zur Hausen
Donna Lavergne
Claire Benton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of EP0972047A2 publication Critical patent/EP0972047A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Definitions

  • the invention relates to a DNA which codes for a peptide of a papillomavirus main capsid protein or a papillomavirus genome. Furthermore, the invention relates to proteins encoded by the papilloma virus genome and antibodies directed against them, and to their use in diagnosis, therapy and vaccination.
  • HP viruses Human papilloma viruses
  • benign e.g. Warts, genital condylomas, and malignancies, e.g. Carcinomas of the skin and uterus, epithelial neoplasms (see Zur Hausen, H., Biochimica et Biophysica Acta (BBA) 1 288, (1 996), pages 55-78).
  • HP viruses are also being considered for the development of malignant tumors in the oropharyngeal area (cf. Zur Hausen, H., Curr. Top. Microbiol. Immunol. 78, (1 977), pages 1-30).
  • Papilloma viruses have an icosahedral capsid without a shell, in which a circular, double-stranded DNA molecule of approximately 7900 bp is present.
  • the capsid comprises a major capsid protein (L1) and a minor capsid protein (L2). Both proteins, coexpressed or L1 expressed alone, lead to the formation of virus-like particles in vitro (cf. Kirnbauer, R. et al., Journal of Virology, (1 993), pages 6929-6936).
  • Papilloma viruses cannot be propagated in monolayer cell culture. Their characterization is therefore extremely difficult, and the detection of papilloma viruses already creates considerable problems. This is particularly true for papilloma viruses in skin carcinomas.
  • the object of the present invention is therefore to provide an agent with which papilloma viruses, in particular in carcinomas of the skin, can be detected.
  • a means should also be provided to treat these papillomaviruses therapeutically.
  • the invention thus relates to a DNA coding for a peptide of a papillomavirus main capsid protein (L1), the peptide representing the amino acid sequence of FIGS. 1, 2, 3, 4, 5, 6 , Fig. 7, Fig. 8 or Fig. 9 or one of them by one or more amino acids different amino acid sequence.
  • L1 papillomavirus main capsid protein
  • Another object of the invention is a DNA coding for a peptide of a papillomavirus main capsid protein, the DNA being the base sequence of FIG. 1, FIG. 2, FIG. 3, FIG. 4, FIG. 5, FIG. 6, FIG 7, 8 or 9, or a base sequence different from one or more base pairs.
  • FIG. 2 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid DL250 at the DSM under DSM 1 1 406 on 1 February 3, 1 997.
  • FIG. 3 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide from L1 of a papilloma virus. That DNA was deposited as plasmid DL253 at DSM under DSM 1 1407 on Feb. 3, 1 997.
  • FIG. 4 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide from L1 of a papilloma virus. This DNA was deposited as plasmid DL267 with the DSM under DSM 1 1 408 on February 3, 1 997.
  • FIG. 5 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was plasmid DL284 at DSM under DSM 1 1409 on the 3rd of February. 1 997 deposited.
  • FIG. 6 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid DL285 with the DSM under DSM 1 1 41 0 on 1 February 3, 997.
  • FIG. 7 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide from L1 of a papilloma virus. This DNA was deposited as plasmid DL287 at DSM under DSM 1 141 1 on February 13, 1 997.
  • FIG. 8 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide from L1 of a papilloma virus. This DNA was deposited as plasmid DL297 at the DSM under DSM 1 141 2 on 1 February 3, 1 997.
  • FIG. 9 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide of L1 of a papilloma virus.
  • This DNA was deposited as plasmid DL332 at the DSM under DSM 1 141 3 on February 1, 1 997.
  • the above DNA was compared to the DNA of known papilloma viruses. Sequence homology studies were carried out. A homology that is less than 90% shows a DNA according to the invention as a new HP virus.
  • the DNAs according to the invention have the following sequence homologies with known papilloma viruses:
  • the above DNA can be present in a vector or expression vector.
  • examples of such are known to the person skilled in the art.
  • these are e.g. pGEMEX, pUC derivatives, pGEM-T and pGEX-2T.
  • yeast e.g. to call pYl OO and Ycpad l
  • animal cells e.g. pKCR, pEF-BOS, cDM8 and pCEV4 must be specified.
  • suitable cells in order to express the above DNA present in an expression vector.
  • suitable cells include the E. coli strains HB101, DH1, x1776, JM101, JM 109 and XU-Blue, the yeast strain Saccharomyces cerevisiae and the animal cells L, NH-3T3, FM3A, CHO, COS, Vero, and Hey.
  • papilloma virus genome comprising the above DNA.
  • the term "papilloma virus genome” also includes an incomplete genome, i.e. Fragments of a papilloma virus genome comprising the above DNA. This can e.g. a DNA coding for L1 or a part thereof.
  • a common method can be used to provide the above papillomavirus genome.
  • a method comprising the following method steps is favorable:
  • epithelial neoplasm encompasses any neoplasms of epithelial tissue in humans and animals. Examples of such neoplasms are warts, condylomas in the genital area and carcinomas of the skin. The latter are lying preferably used to isolate the above papillomavirus genome.
  • vector includes any vector suitable for cloning chromosomal or extrachromosomal DNA.
  • examples of such vectors are cosmids such as pWE1 5 and Super Cos1, and phages such as ⁇ -phages, e.g. ⁇ ZAP Expressvector, ⁇ ZAPII Vector and ⁇ gt10 Vector.
  • ⁇ phages are preferably used.
  • the above vectors are known and are available from Stratagene.
  • Papillomavirus genomes according to the invention can be integrated in chromosomal DNA or extrachromosomal. Methods are known to the person skilled in the art to clarify this. He also knows how to find the optimal restriction enzymes for cloning the papillomavirus genomes. It will be based on genomes of known papilloma viruses. In particular, the person skilled in the art will observe the aforementioned HP viruses accordingly.
  • a papilloma virus genome designated DL231 -G is described by way of example.
  • the total DNA is isolated from a biopsy of a squamous cell carcinoma, cleaved with BamHI and electrophoretically separated in an agarose gel.
  • the agarose gel is then subjected to a blotting process, whereby the DNA is transferred to a nitrocellulose membrane.
  • This is used in a hybridization process in which the DNA from FIG. 1, possibly in combination with a DNA from HP virus 5c, is used as the labeled sample. Hybridization with the papilloma virus DNA present in the total DNA is obtained.
  • the above total DNA cleaved with BamHI is cloned in a ⁇ phage.
  • the corresponding clones ie the clones containing the papillomavirus DNA, are identified by hybridization with the DNA from FIG. 1, possibly in combination with a DNA from the HP virus 5c.
  • the insert of these clones is then subjected to a further cloning in a plasmid vector, whereby a clone is obtained which contains the papillomavirus genome DL231 -G.
  • the genome is confirmed by sequencing.
  • papillomavirus genomes are provided. They are named according to the DNAs used for their preparation, with: DL250-G, DL253-G, DL267-G, DL284-G, DL285-G, DL287-G, DL297-G or DL332-G.
  • Another object of the invention is a protein encoded by the above papillomavirus genome.
  • a protein is e.g. a major capsid protein (L1) or a minor capsid protein (L2).
  • L1 or L2 of the papilloma virus genome DL231 -G is described as an example.
  • the HP virus 5c which is related to the DNA of FIG. 1, is used for this purpose.
  • the complete sequence and the position of individual DNA regions coding for proteins are known from this.
  • These DNAs are identified on the papillomavirus genome DL231 -G by parallel restriction cleavages of both genomes and subsequent hybridization with different fragments relating to L1 or L2 coding DNA. They are confirmed by sequencing.
  • the DNA coding for L1 is called DL231 -G-L1 DNA and the DNA coding for L2 is called DL231 -G-L2 DNA.
  • the DNA coding for L1 or L2 is inserted into an expression vector.
  • E. coli examples of such for E. coli, yeast and animal cells are mentioned above.
  • vector pGEX-2T for expression in E. coli (cf. Kirnbauer, R. et al., Supra).
  • pGEX-2T-DL231 -G-L1 or pGEX-2T-DL1 7-G-L2 is obtained.
  • these expression vectors express a glutathione S-transferase-L1 or glutathione S-transferase-L2 fusion protein. These proteins are purified in the usual way.
  • the Bacculovirus or vaccinia virus system called.
  • Expression vectors that can be used for this are, for example, pEV mod. and pSynwtVI " for the bacculovirus system (cf. Kirnbauer, R. et al., supra).
  • vectors with the vaccinia virus are in particular" early "(p7. 5 k) - or” late "( Psynth, pl 1 K) promoter (cf. Hagensee, M., E.
  • the bacculovirus system is preferred DNA encoding L1 or L2 in pEV mod. PEVmod.-DL231 -G-L1 or pEVmod.-DL231 -G-L2 is obtained.
  • a particle comprises an L1 protein
  • an L1 protein in the latter case it contains an L1 protein as well as an L1 protein.
  • a virus-like particle of the latter case is also obtained by inserting the above DL231 -G-L1 and DL231 -G-L2 DNAs together into the expression vector pSynwtVI " and the obtained pSynwtVI " DL231 -G-L1 / L2 for infection of SF-9 insect cells is used.
  • the above virus-like particles are cleaned in the usual way. They also represent an object of the invention.
  • Another object of the invention is an antibody directed against an above protein or virus-like particle.
  • Such is produced in the usual way. It is described by way of example for the production of an antibody which is directed against a virus-like particle comprising L1 of DL231 -G.
  • the virus-like particle BALB / c mice is injected subcutaneously. This injection is repeated every 3 weeks. About 2 weeks after the last injection, the serum containing the antibody is isolated and tested in the usual way.
  • the antibody is a monoclonal antibody.
  • the mice are produced Spleen cells removed and fused with myeloma cells in the usual way. The further cloning is also carried out according to known methods.
  • the present invention makes it possible to detect papilloma viruses, in particular in carcinomas of the skin.
  • the DNA according to the invention can be used as such or encompassed by a further DNA.
  • the latter can also be a papilloma virus gome or part of it.
  • the present invention also enables the provision of previously unknown papilloma viruses. These are found particularly in carcinomas of the skin. Furthermore, the invention provides proteins and virus-like particles which are due to these papillomaviruses. Antibodies are also provided which are directed against these proteins or particles.
  • the present invention thus makes it possible to take diagnostic and therapeutic measures for papillomavirus diseases. In addition, it provides the opportunity to build a vaccine against papillomavirus infections.
  • the present invention thus represents a breakthrough in the field of papilloma virus research.
  • Example 1 Identification of the papilloma virus genome DL231 -G
  • the total DNA is isolated from a biopsy of Verruca vulgaris. 10 yg of this DNA are cleaved with the BamHI restriction enzyme and electrophoresed in a 0.5% agarose gel. At the same time, 10 ⁇ g of the above DNA, which has not been cleaved, are also separated.
  • the agarose gel is subjected to a blotting process, whereby the DNA from the agarose gel is transferred to a nitrocellulose membrane. This is used in a hybridization process in which the above 1 in combination with HP virus 5c DNA is used as the p 32 -labeled sample. Hybridization with the blotted DNA is obtained.
  • Example 2 Cloning of the papilloma virus genome DL231 -G
  • the biopsy DNA obtained from Example 1 is cleaved with the restriction enzyme BamHI.
  • the fragments obtained are used in a ligase reaction in which the BamHI-cleaved and dephosphorylated vector ⁇ ZAP Express is also present.
  • the recombinant DNA molecules obtained in this way are packaged in bacteriophages and used to infect bacteria.
  • the ZAP Express Vector Kit offered by Stratagene is used for these process steps.
  • the phage plaques obtained are then subjected to a hybridization process in which the p 32 -labeled DNA from FIG. 1 used in Example 1 is used in combination with p 32 -labeled HP virus 5c DNA. Hybridization with corresponding phage plaques is obtained.
  • the BamHI fragments of DL231 -G are isolated from these and used together with a BamHI-cleaved, dephosphorylated plasmid vector, pBluescript, in a further ligase reaction.
  • the recombinant DNA molecules obtained are used to transform bacteria, E. coli XL1-Blue.
  • a bacterial clone containing the papillomavirus genome DL231 -G is identified by restriction cleavage or hybridization with the above DNA samples.
  • the plasmid of this bacterial clone is designated pBlue-DL231 -G.

Abstract

L'invention concerne un ADN qui code un peptide d'une protéine de capside principale de papillomavirus ou un génome de papillomavirus. L'invention concerne également des protéines codées par le génome de papillomavirus et des anticorps dirigés contre elles ainsi que leur utilisation pour le diagnostic, la thérapie et la vaccination.
EP98928070A 1997-03-25 1998-03-24 Proteines a capside principale de papillomavirus et leur utilisation a des fins de diagnostic, de therapie et de vaccination Withdrawn EP0972047A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19712541A DE19712541C1 (de) 1997-03-25 1997-03-25 Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19712541 1997-03-25
PCT/DE1998/000876 WO1998042847A2 (fr) 1997-03-25 1998-03-24 Proteines a capside principale de papillomavirus et leur utilisation a des fins de diagnostic, de therapie et de vaccination

Publications (1)

Publication Number Publication Date
EP0972047A2 true EP0972047A2 (fr) 2000-01-19

Family

ID=7824586

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98928070A Withdrawn EP0972047A2 (fr) 1997-03-25 1998-03-24 Proteines a capside principale de papillomavirus et leur utilisation a des fins de diagnostic, de therapie et de vaccination

Country Status (5)

Country Link
US (1) US6610303B1 (fr)
EP (1) EP0972047A2 (fr)
JP (1) JP2001520519A (fr)
DE (1) DE19712541C1 (fr)
WO (1) WO1998042847A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
DE19735118C1 (de) 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7094541B2 (en) 2001-08-31 2006-08-22 Gen-Probe Incorporated Assay for detection of human parvovirus B19 nucleic acid
AU2011258501B2 (en) 2010-05-25 2016-07-07 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2661921B1 (fr) * 1990-05-11 1992-08-07 Pasteur Institut Sonde a papillomavirus (hpv66), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus.
DE19526386C1 (de) * 1995-07-19 1997-01-02 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19648962C1 (de) * 1996-11-26 1998-02-26 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9842847A2 *

Also Published As

Publication number Publication date
WO1998042847A2 (fr) 1998-10-01
JP2001520519A (ja) 2001-10-30
WO1998042847A3 (fr) 1999-03-11
DE19712541C1 (de) 1998-11-05
US6610303B1 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
EP0809700B1 (fr) Particules semblables au virus du papillome, proteines de fusion et leur procede de production
DE19543553B4 (de) VP-Antigene des JC-Virus
DE69836753T2 (de) Papilloma virus capsomere impfstoff-formulierungen und deren verwendungen
DE69531308T2 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
DE69631586T2 (de) Für menschliches papillomavirus stamm 18 kodierende dns
DE4415743C2 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19526386C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE69933875T2 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
DE19648962C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19735118C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19712541C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE4447664C2 (de) Fusionsproteine, Verfahren zu deren Herstellung sowie deren Anwendung
DE19840263C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE10059631A1 (de) T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie
DE4332596A1 (de) Monoklonale Antikörper
DE19526752C2 (de) Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
DE19649606C1 (de) Systeme zur Bestimmung von Wirksubstanzen gegen HPV-assoziierte Karzinome
WO1999048917A2 (fr) Formulation contenant une proteine specifique des papillomavirus, sa fabrication et son utilisation
WO2002055542A2 (fr) Peptides specifiques du virus du papillome humain (hpv) qui bloquent la liaison entre ledit virus et la cellule hote
DE19905883C2 (de) Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
DE19518488C1 (de) Autoantigen, geeignet zur Feststellung einer Thromboseneigung
DE19520421A1 (de) Autoantigen, geeignet zur Feststellung einer Thromboseneigung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990921

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20031203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040716